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1 EXECUTIVE SUMMARY 
In many developed countries, including Switzerland, the ongoing increase in life expectancy is driven by the 
mortality decline among older persons. This has important consequences for both the provision of health 
care and the management of pension funds. 
In this context, the Swiss Federal Office of Statistics mandated a small group of experts to provide a critical 
review on the future evolution of mortality in developed countries. The report starts with an analysis of the 
past trends in life expectancy. Longevity is defined here as the duration (or the length) of life as observed in 
population or in individuals. The oldest and still most used indicators of longevity are life expectancy at birth 
(LE0) at a population level, and maximum life span (MLS) at the individual level. (page 9) and in healthy life 
expectancy (page 19). A discussion on the future evolution of mortality and health is then presented (page 
27). A set of recommendations is finally proposed (page 39).  
1.1 PAST AND CURRENT TRENDS IN LONGEVITY AND HEALTH 
In Switzerland, life expectancy at birth (LE0) continues a steady increase that began at the end of the 19th 
century, while LE65 showed an increase since the 1950s. As in other countries, there is no clear sign that the 
rise in LE0 might come to an end, although the yearly increase is slower since the 1980s. 
The modal age at death, which can be seen as the "usual" mean longevity at a given time, increased steadily 
since the 1920s. Among the adults, the variability of age at death decreased during the last fifty years, 
compatible with a compression of mortality. 
There is however no fate dictating that LE0 should continue on the same line. A plateau of LE0, or even a 
decline, has been observed in several European countries, probably related to crises affecting the socio-
economical environment, the life styles (e.g., alcohol and tobacco use), or the supply of health services. 
Healthy life expectancy, as measured by the number of years spent without disability (DFLE), increased 
during the last fifty years, due to a decrease of age-specific disability prevalence. However, international 
trends in DFLE are heterogeneous, with some countries showing stability or even decrease in the proportion 
of years spent without disability after age 65. Whether these results indicate real variation or differences in 
measurement of disability is still undetermined.  
1.2 FUTURE EVOLUTION OF LONGEVITY AND HEALTHY LIFE EXPECTANCY 
Most projections of LE use historical trends in mortality rates or life expectancy as an input. Such an 
approach is based on the remarkable stability of the changes over the past 200 years. However, most 
projections based on past trends consistently underestimated the increase in LE. 
Epidemiological approaches use information on the determinants of mortality by cause of death (e.g. 
smoking, obesity…) ; they provide results that are not very different from those of extrapolative methods. 
In summary, most methods predict that LE0 will increase up to 2050 in men as in women in industrialized 
countries such as Switzerland, with estimates ranging from five to nine years adding to the current figures. 
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Previsions of healthy life expectancy rely on projected total life expectancy, combined with projections of the 
prevalence of disability. Available estimates predict a longer DFLE in Switzerland. These previsions are often 
criticized because they fail to capture the complexity of the determinants of disability and the difficulty to 
interpret any trend (e.g., the development of new assistive technologies might have contributed to the 
decline in reported disability). 
According to epidemiological projections, major upheaval in health would have a limited impact on health-
adjusted life expectancy: in the absence of 20 major risk factors for diseases and injuries, the health-adjusted 
life expectancy would increase by about 5 years as compared to the current situation in 2000. 
1.3 RECOMMENDATIONS 
There is currently no definite argument in favour of a specific method of prevision. Thus, we recommend to 
provide estimates based on several methods, e.g., (i) a method using a set of observed lowest mortality rates 
at a given time, (ii) a method using the epidemiological projections of the determinants of mortality (e.g., 
smoking, diet, etc.), and (iii) a method estimating the effect of the projected evolution of education and 
socio-economic status on the future mortality rates. 
When using historical periods to establish future trends, the historical period should be at least as long as the 
projection period. Further, the mortality experience of other populations should be assessed, and cohort 
effects should be carefully considered. 
A closer monitoring of longevity is needed. This means that mortality rates of the oldest-old should be 
followed up not only with cross-sectional estimates, but also with appropriate cohorts. 
Another aspect is to rethink the system of cause of death because of its currently low information content. 
Finally, in order to develop methods using health related information, epidemiological knowledge on the 
oldest population should be improved through health surveys, which should also include those living in 
institutions. 
A committee on the future of longevity and healthy life should be set up to further address these issues.
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2 INTRODUCTION 
In many developed countries 1, including Switzerland 2, the ongoing increase in life expectancy is driven by 
the mortality decline of the old and the very old persons.  Further, because the main causes of death are 
related to slow, degenerative diseases (cardiovascular and cancer are responsible of 60% of causes of death in 
people aged more than 60), the determinants of mortality take place in the adult life, or even before 3. 
In this context, the Swiss Federal Office of Statistics decided to mandate a small group of experts to 
summarize the current information on past trends in mortality and longevity, as well as on their future 
evolution in Switzerland and other industrialized countries. The scope of this report is to provide a critical 
review of the literature on the future evolution of mortality in developed countries and some suggestions 
regarding the most promising approaches of projections. This report will also address the health of the older 
persons, in the perspective of the healthy life expectancy. 
The first two chapters start with a couple of definitions, then with an analysis of the past trends in life 
expectancy and health indicators. The future evolution of mortality and health are presented in the two next 
chapters. A set of recommendations is finally developed, on the strategies of and on what is needed in term 
of information for monitoring and projecting longevity. 
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3 PAST AND CURRENT TRENDS IN MORTALITY AND 
LONGEVITY 
3.1 DEFINITIONS 
Longevity is defined here as the duration (or the length) of life as observed in population or in individuals. 
The oldest and still most used indicators of longevity are life expectancy at birth (LE0) at a population level, 
and maximum life span (MLS) at the individual level. 
Several other indicators have been proposed to overcome the limitations of both LE0 and MLS. They allow 
examining more closely the patterns of old age mortality. These indicators are increasingly used, including in 
this report. They are briefly presented below. 
Indicators of longevity: 
• Life expectancy at birth (LE0), or at any age x (LEx): An estimate of the average number of additional 
years an individual could expect to live if the age-specific death rates for a given year prevailed for the 
rest of his life a. It is the mean duration of life in a population at a given calendar time. LE0 is still a 
popular indicator of longevity 4-9, but it is sensitive to early mortality, in particular to child and infant 
mortality. This is a drawback when late mortality is the driving force of longevity 10-12. 
• Median age at death (Med): age that separates the younger half of the deceased from the older half. Med 
is usually given as the average value of the yearly median ages within a period of study. 
• Modal age at death (M): the most common age at which adult people die (i.e. age with the maximum 
number of deaths) at a given period. M is sometimes difficult to estimate because of the flatness 
around the modal area 13, and smoothing techniques are in general needed. M is a companion 
indicator of the "normal life duration", a concept introduced by Lexis in 1878 14. Briefly, the concept 
distinguishes three parts in the mortality of a population: (i) one part related to infant and child 
deaths, i.e., premature mortality, (ii) another part related to aging-related deaths (i.e., the late mortality 
or the "normal" deaths) and (iii) an intermediate part where premature and aging-related deaths 
overlap. In this perspective, M was viewed by Lexis as the central value around which aging-related 
deaths are normally distributed (i.e., the mode is an estimate of the arithmetic mean of the normal life 
duration), although this is wrong, as mortality is skewed towards younger ages, with the mode higher 
than the mean. According to this hypothesis, the right-hand side of the distribution of age of deaths 
(deaths occurring after M) gives the parameters of a normal distribution centred on M (i.e., the left-
hand side of the distribution is constructed by symmetry of the right-hand side). Kannisto later 
suggested that M and the standard deviation above it provide a good account of longevity under a 
given mortality regime 15. 
• Maximum life span (MLS): the maximum number of years a member of a population has been observed 
to survive, at a given period. MLS has the advantage to be based on straightforward information, that 
may however be of poor quality, due to the inaccuracy of reported ages of very old persons. Also, as a 
single event, it depends on the size of the population under study, although this might not be the 
major determinant of change in MLS. In Sweden for example, MLS increased from 101 years to 108 
years between the 1860s and the 1990s. Of this increase, 72.5% is attributable to a decline in mortality 
above age 70, only about 12% to the increasing size of successive birth cohorts, and about 16% to 
mortality reductions below age 70. 
• Life endurancy: the age reached by 1 per 10’000 (or 1 per 100’000) individuals of a cohort. 
                                                     
a  See website: www.prb.org 
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• Number of deaths at age 100 and over: as the absolute number of deaths occurring at age 100 and over, 
this indicator also depends on the size of the population. 
• Number of centenarians/supercentenarians: number of persons aged 100 and over, respectively 110 years 
and over, at a given period in a population. It also depends on the size of the population.    
• Centenarian rate (CRx): incidence of centenarians in a given cohort, estimated by the number of 
survivors aged 100 at a given date divided by the size of the corresponding cohort at age x (for 
example: CR80 is the number of centenarians observed in a cohort of people alive 20 years before, i.e. 
when they were aged 80 years). 
Indicators of concentration, verticalization and rectangularization: 
• Rectangularization of the survival curve: pattern of mortality characterized by an important proportion of 
persons surviving until old age and dying over a short period of time (i.e., with a compression of 
mortality within a short period). 
• Standard deviation above the mode (SD(M+)): measures the dispersion of the deaths occurring above the 
modal age at death. When SD(M+) decreases, then the survival curve becomes more rectangular. 
3.2 LONGEVITY AND MORTALITY 
Most of the available studies are based on population census and vital statistics, i.e., on an information 
system available only since the mid-19th century in the developed countries. 
A substantial amount of information is provided by demographic history 16 on the pre-modern patterns of 
mortality, including in Switzerland. Although this literature will not be commented here, at least one 
observation deserves attention. In Europe, there is a slow and steady increase of the life expectancy at birth 
(LE0) since the Middle-Age, i.e., well before the sanitary and hygienic reforms of the late 19th century 17, 
possibly in relation with factors such as diet, infectious environment, etc... This raises the possibility that 
future changes in mortality might be determined by unexpected changes of currently unknown factors.  
Although LE0 is not the most appropriate indicator in countries where mortality is low among young and 
middle-aged people18, it is still the most widely used indicator of longevity, and hence, the most widely 
available. It also has the advantage of being easily interpreted. The paragraphs below provide an analysis of 
the recent evolution. 
Figure 1 shows that LE0 has increased steadily in Switzerland since 1876, from about 40 and 42 years for 
men and women, respectively, to the current values of 79 and 84 years 2. In other words, LE0 almost 
doubled in both genders, with a yearly increase amounting to about 4 or 5 months from 1876 until 1950, 
slightly faster among women than among men. It then dropped off to a slower rhythm, about 3 months per 
year, during the period 1950-2000. 
The increase in LE0 was first attributable to the decline in infant and childhood mortality (which probably 
started in the first half of the 19th century).  
 11 
 
In the 1950s, a new pattern of evolution emerged: (i) LE60 and LE80 began to increase in both gender, and (ii) 
a gender gap in LE0 appeared and widened, with women gaining more years of LE0 than men. This gap is 
partially attributable to causes of death (e.g., cardiovascular or cancer) which are sensible to lifestyle habits 
(e.g., smoking or alcohol use). The gap peaked in the 1970s. Since the 1980s, the gender gap diminished, 
partially due to the evolution of lung cancer mortality, much more favourable among men than among 
women 19. 
Figure 1.  Life expectancy at birth (LE0), at age 60 (LE60), and at age 80 (LE80), by gender. 
Switzerland, 1876-2000 (Source: Robine J-M, Paccaud F. 2005 2) 
 
 
Figure 2 shows the evolution of both the modal age at death (M) and the maximum age at death (MLS). The 
rising trends of both indicators are less marked than the one of LE0. M increased from 70 to 84 years for 
men, from 70 to 88 years for women. 
M started to increase well after LE0. Before the 1920s, M did not change, fluctuating between 70 and 75 
years. In women, M increased at a rhythm of two months per year, from 75 years in 1921-1925 to almost 90 
years in 2001-2005. In men, M increased at a slower pace (less than half a month per year) from the 1920s 
until 1946-1950. It then ran in parallel with the women. Overall, the pattern of increase is similar across 
genders, although faster for women. 
In both gender, there is a secular decline of the difference between M and LE0, from 30 years (about 70% of 
LE0) to 6 years (about 7%), related to the decline in children mortality that previously had a major impact on 
LE0. 
The same Figure 2 shows the increase in MLS, with an acceleration from the 1950s. MLS was about 102 
years between 1880 and 1920, then reached 104 years between 1920 and 1960. It currently reaches 110 years, 
with higher values for women than for men. The pattern of increase is similar across genders. 
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Figure 2.  Secular trends in modal age at death (M) and in maximum life span (MLS, in both 
genders. Switzerland, 1876-2002. (Source: Cheung, Robine, Paccaud, et al., 
personal communication) 
 
 
 
Another indicator reflecting the decline in old age mortality is the number of deaths occurring at age 100 and 
over, that began to increase in the 1950s, as shown in Figure 3. Although there is a large difference in the 
absolute numbers of male and female centenarians, the increase rate is similar across genders, as shown in 
the insert of the same Figure 3. 
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Figure 3.  Number of deaths at age 100 and over, by gender, Switzerland, 1940-2000 (Insert 
show the same data, with the number of deaths on a log scale). (Source: Robine J-
M, Paccaud F. 2005 2) 
 
Table 1 disentangles the determinants of the increase in centenarians, from the cohort 1870 to the cohort 
1900. For females, the number of centenarians has increased by a factor of 12.5. One part is due to the 
increase in the cohort size by a factor of 1.2. The remaining effect is attributable to the mortality drop, 
which is broken down into (i) an effect of early mortality (between birth and age 80), and (ii) an effect of 
late mortality (between 80 and 100). The multiplicative model for the increase in centenarians thus 
includes three factors of change (size of the birth cohort and two elements of mortality) to determine the 
increase in female centenarians (1.2 * 2.3 * 4.5 = 12.5). According to this, the drop in mortality after 80 
explains more than half of this increase, the drop in mortality from birth to 80 explains another third. 
Similar proportions can be found among males, as shown in the same Table 1. 
Table 1.  Determinants of the increase in the number of centenarians: cohort size at 
selected ages and increase factors. Switzerland, 1870 and 1900  (Source: Robine J-
M, Paccaud F. 2005 2) 
 Males females 
 1870 1900 factor 1870 1900 factor 
Cohort sizes              
At birth 40,570 48,223 1.2 38,638 46,093 1.2 
at 80 4,086 9,065 2.2 6,185 17,304 2.8 
at 100 9 53 6.2 23 294 12.5 
 
As a result, the number of people aged 100 and more increased rapidly, more than doubling every ten years. 
Note that the centenarians doubling time shortened over time. This is shown in Figure 4. 
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Figure 4.  Number of people aged 100 and more. Switzerland, census data, 1860-2000. 
(Source: Robine J-M, Paccaud F. 2005 2) 
 
Table 2 shows the centenarian rates at birth (CR0) and at 60 (CR60) (see definition above). CR0 and CR60 
increased in both genders. Overall, CR0 varied from 1.5 centenarians per 10,000 births in 1860 (.8 for males, 
2.2 for female) to 38.6 in 1900 (11.6 for males, 66.8 for females). The increase was more marked among 
females. 
As expected, values are higher for CR60, but follow a similar pattern: CR60 increases from 2 to 22 for males, 
from 5 to 100 for females. A slowing down in the increase of CRs is apparent since the 1980s. 
The advantage of females over males is striking: female CR0 is always larger than male CR60, and this 
advantage increases over the period. The same Table 2 shows that the ratio CR60/CR0 is always larger among 
males than among females, suggesting that the selective effect of early mortality is stronger for males than 
for females. A further point to note is that, in both genders, the ratio CR60/CR0 decreases over the period: 
this is compatible with a stronger decrease in mortality after the age of 60 than before this age. 
Table 2.  Centenarian rates for cohorts at birth (CR0) and at age 60 (CR60). Switzerland, 
centenarians at census 1960, 1970, 1980, 1990 and 2000. (Source: Robine J-M, 
Paccaud F. 2005 2) 
 CR0 CR60 Ratio CR60/CR0 
  males Females males Females Males Females 
1960 0.8 2.2 2.2 4.8 2.8 2.2 
1970 2.2 6.5 5.7 13.7 2.6 2.1 
1980 5.6 16.3 13.5 32.1 2.4 2.0 
1990 6.2 38.2 13.0 62.6 2.1 1.6 
2000 11.6 66.8 21.6 99.3 1.9 1.5 
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There are several ongoing studies on the mortality trends in older people in Switzerland. In general, the 
observations are compatible with a compression of mortality. This was already visible in an earlier work, 
suggesting a narrowing of the distribution beyond the mean age at death 20. This can be seen on Figure 5, 
showing the evolution of the pattern of distribution of age at death for four periods in women. 
Figure 5.  Distribution of age at death: empirical (dots) and fitted densities (lines). Women, 
Switzerland, four periods (from left to right: 1876-80, 1906-10, 1956-60 and 2001-2) 
(Source: Cheung, Robine, Paccaud, et al., personal communication) 
 
 
Demographic information show a continuing decrease of mortality even in low mortality populations, 
suggesting that there is still further room for improvement in mortality and life expectancy. In other words, 
the current pattern is a compression of mortality occurring around an increasing mean age of death. 
3.3 OTHER COUNTRIES 
Figure 6 shows LE0 as reported for 2005 in selected countries, including Switzerland for comparison 
purposes. Two observations are worth mentioning. First, in all countries, there is a substantial gap between 
women and men. Although biological differences make the gender gap likely to persist, this variability can be 
interpreted as a possible room for improvement for males. Second, even among the developed countries 
displayed in this Figure, there is a gap of about 6-7 years in LE0. Again, these gaps are important because 
they quantify possible gains for those with the low values of LE0. 
  
Women 
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Figure 6.  Life expectancy at birth (LE0) in selected countries, by gender. OCDE, 2005 
(www.oecd.org). 
 
Comparing longevity between countries is difficult prior to the 20th century, due to the scarcity of credible 
data. In general, most European countries show a pattern similar to the one observed in Switzerland, often 
with a gap of a couple of years: LE0 is increasing since the middle or the end of the 19th century, and 
continued to increase throughout the 20th century (see Figure 9, page 43 and Figure 10, page 43). 
With LE0 reaching 75 and 85 years in men and women, respectively, Japan is enjoying the highest LE0 
worldwide in 2002. 
In the US, trends in LE0 from 1900 to 2000 also show a steady increase, however less marked since the 
1980s 21. As compared to the highest figures recorded, US LE0 was 10 years shorter in the early 20th century, 
and then converged to the highest life expectancies, with a current deficit of one year in 2000 22. LE0 
increased from 68.2 years in 1950 to 77.8 years in 2004. LE65 and LE85 increased from 13.8 years and 4.7 
years, respectively, in 1950 to 18.7 years and 6.8 years, respectively, in 2004 23. 
A closer look to European data suggests that the evolution of European LE0 followed a pattern common to 
all countries until the 1940s and the 1960s (Source: European Health Expectancy Monitoring Unit, 
www.ehemu.org). After that, the evolution of LE0 followed three specific patterns (see Figure 11, p. 44, and 
Figure 12, p.45): 
• a group of "high convergence" countries (which includes Switzerland), in which the LE0 did increase 
steadily (i.e., without slowing down during the 1960s), resulting in the currently highest LE0 in Europe 
(83-84 years for women, 78-79 years for men); 
• a group of "low convergence" countries (which includes England and Wales, Belgium) which is 
characterized by a slowdown in the LE0 increase during the 1960s. LE0 then converged in the 1970s 
to a value which is about two years below the LE0 reached by the "high convergence" countries.  
• a group of "divergent" countries, which include most of the Eastern Europe countries, but also 
Denmark, Norway and the Netherlands, show a plateau or even a decrease in LE0.  
These three patterns of evolution result in significant differences in LE0 between European countries, 
reaching a maximum of twelve years for men and seven years for women in 2002-2003 (when comparing 
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countries of the Eastern Europe and countries like France or Switzerland). Most recent data suggest that the 
divergence is enduring. In the Netherlands, for example, an unexpected and sudden reversal in old-age 
mortality decline occurred around 1980, leading to a decrease in life expectancy in men, and to a plateau in 
women. 
The reasons underlying the make-up of these three groups are unclear. They are likely to be related to crises 
in the social and health environments, perhaps common among the countries belonging to the same group 
of pattern of evolution 24;25. As noted by Bongaarts 26, this divergence in Western Europe is largely due to 
differences in smoking mortality. Regarding the Netherlands, trends in smoking mortality are a partial 
explanation for the stagnation in mortality decline, and other factors are difficult to identify, as their relation 
to specific causes of deaths is unclear24. Moreover, inaccuracies and secular changes in the coding of causes 
of deaths make these analyses complex. Several detailed analyses of the situation have been produced in the 
Eastern countries 27-29, including by an international group based in Warsaw b. Analysis of causes of death are 
not very useful, because of the poor quality of the data for deaths occurring after 80 years 30. 
The trends in LE65 are shown in Figure 13, p. 46 and Figure 14, p. 46. In most European countries, the 
decrease in old age mortality became obvious from the 1950s onwards. Globally, LE65 showed a one-year 
increase between 1996 and 2002. In 1996, the largest differences between European countries reached five 
years in both genders. 
The modal age at death (M) was fluctuating between 65 and 75 years throughout the 18th and 19th century, 
and began to increase steadily from the end of the 19th century. Since the 1960s, M tends towards a value of 
90 years for women in most European countries. 
The higher M in female is observable from the beginning of the 20th century and reached a maximum in the 
1970s. Since then, M also increases in men, although not enough to reduce the gender difference.  
Sweden provides data on maximum life span (MLS) since 1861. There is a clear upward trend (more 
pronounced after 1969), increasing by 1.1 year per decade 31;32. Similar trends are observed in other 
European countries and in Japan 33-36. Part of this trend is attributable to the decrease of mortality in the 
oldest-old, adding to the larger number of survivors to old age and to larger birth cohorts 37. 
                                                     
b  http://hem.waw.pl 
 18 
 
In Japan, from 1950 to 2004, M increased steadily from 73.7 years to 84.7 years in men, from 78.0 to 90.2 
years in women 38, i.e., 2.5 months per year. There is no sign of a slowing down for the increase of M, but 
the standard deviation above the mode (SD(M+)), a measure of the distribution of death, decreased steadily 
until the 1990s in men and the mid-1980s in women. The SD(M+) then reached a plateau. The number of 
death occurring at and above the mode continued to increase, but at a slower pace than in the mid-seventies. 
These observations are compatible with a compression of mortality, that still continues but at a much slower 
pace, as SD(M)+ remains constant. 
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4 PAST AND CURRENT TRENDS IN HEALTHY LIFE 
EXPECTANCY 
To improve the understanding of the report, the following definitions of the indicators of healthy life are 
given: 
• Healthy life expectancy (HLE): average number of years an individual is expected to live in a 
specific health state. There are many possible dimensions of health, therefore many different health 
expectancies. In practice, HLE is often used as a generic name for the indicators combining 
mortality and health status. 
• Health-adjusted life expectancy (HALE): Average number of years that a person can expect to live 
in "full health" by taking into account years lived in less than full health due to disease and/or 
injury c. 
• Disability-free life expectancy (DFLE): average number of years an individual is expected to live 
without disability, i.e. without limitation in daily living activities such as bathing, dressing, walking, 
etc. DFLE combines age-specific mortality with age-specific prevalence of disability (more rarely, 
with age-specific incidence of disability). Like LE, DFLE may be computed at each age x. 
• Ratio DFLEx/LEx: ratio of disability-free life expectancy over total life expectancy, reflecting the 
proportion of remaining years (after age x) that are spent without disability. 
LE0 is a relevant health indicator as far as morbidity is dominated by rapidly lethal diseases. The increasing 
prevalence of degenerative and chronic diseases means that an increasing proportion of the population will 
suffer from diseases with a low risk of dying from them. Further, an important proportion of the population 
will suffer from disability following from degenerative diseases 39. 
The relationship between longer life expectancy and health has been examined by Fries40, who considered 
three scenarios of evolution 41 (see Figure 7). According to the paradigm of compression of morbidity, the 
average age at first chronic disease or disability is postponed (III in Figure 7): if this postponement is larger 
than the increase in life expectancy, people will gain years of healthy life or, in other words, the period of 
morbidity from chronic diseases will be compressed at the end of life. 
Another scenario (I in Figure 7) postulated a longer life with a constant age at the beginning of morbidity, 
i.e., an expansion of morbidity. Finally, the scenario II on Figure 7 assumes that the age at death increases in 
the same amount as the increase of the age of the incidence of degenerative disease: this is simple shift 
towards a longer life with a stable duration of unhealthy life. 
                                                     
c  www.who.int/whosis 
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Figure 7.  Possible scenarios for future morbidity and longevity. (Source: Fries 2005 41) 
 
 
In this context, new indicators have been developed since the mid-20th century, in order to take into account 
not only the years of life enjoyed by the population, but also the quality of life 42. The concept of health 
expectancies was first proposed by Sanders in 1964 43, and then formalized by Sullivan who proposed a 
method to compute health expectancies 44. This method is based on the age-specific prevalence of healthy 
and unhealthy states (data gathered in cross-sectional health surveys) combined with age-specific mortality 
(from standard period life table). 
An alternative, less convenient, approach is the multi-stage method, that uses incidence of health states 
instead of prevalence data and thus requires longitudinal observation to provide the transition rates between 
health states. 
Many researchers have commented on the differences between the methods. Both seem equivalent when 
transition rates are smooth and regular over time 45. The Sullivan method can be generally recommended for 
its simplicity, its relative accuracy and the ease of interpretation. 
As disability often represents the cumulative consequence of chronic diseases 46, disability-free life 
expectancy (DFLE, see also above) is a commonly used indicator of healthy life. This concept further allows 
to split life expectancy into years lived with and without disability. The assessment of aging populations 
commonly uses DFLE65 in absolute number and as a proportion of LE65. DFLE has been criticized as not 
incorporating information related to the severity of disability. 
In contrast to mortality, information on disability has been collected over a shorter period, mainly from the 
1980s, and in fewer countries. Comparing disability-related figures is therefore difficult, also because of 
differences in the definitions used (based on the presence of any incapacity in activities of daily living, for 
example in Katz’ scale 47, or in instrumental activities such as walking outside home, shopping, preparing 
meals).  
Another problem is the difference in sampling: typically, the prevalence of disability is underestimated when 
measured only in community-dwelling persons, i.e., omitting institutionalised residents who are at higher risk 
of being disabled. Note that the Swiss Health Survey (an interview survey on a Swiss-wide sample of 20'000 
community-dwelling persons since 1992) will include a sample of institutionalized persons from the 2007-8 
survey on. More generally, the classical selection bias affecting all health surveys, with a disproportionate 
number of disabled persons among non-participants, is especially important in aged population, where the 
prevalence of disability is high. 
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Figure 8 displays DFLE0 in year 2002 in various countries. In all countries, DFLE0 is higher among women 
than among men, although the difference is less striking than for LE0. 
Figure 8.  LE0 by gender, with disability (DLE0) and without disability (DFLE0). Selected 
countries, 2001 (Source: Mathers 2003 48) 
 
In Switzerland, between 1981 and 1997, the increase in DFLE0 paralleled the increase in LE0 49. This 
increase was observed in both genders (see Table 3). The simultaneous increase in both DFLE0 and LE0 
suggests that the population is enjoying an "healthy ageing", i.e., ageing means here adding both years to life 
and life to years. 
LE65 and DFLE65 also showed an increase, although the gender difference is more marked: the proportion of 
years spent without disability (ratio DFLE65/LE65) varies according to the gender. Between 1981 and 2002, a 
compression of morbidity is observed in men as in women: the ratio DFLE65/LE65 increased from 79% to 
83% for men, from 66% to 75% for women, in a context of strong increase of LE65 in both gender, from 
14.6 to 17.5 years and from 18.5 to 21.1 years, for men and women respectively. 
Both the 2002 figures and the evolution of the compression of morbidity between 1981 and 2002 vary 
between the genders. Between 1981 and 1997, women gained years of life without disability and experienced 
a decline in the number of disabled years: the proportion of years with disability significantly thus decreased 
in women, an evolution compatible with a compression of morbidity. 
During the same period, men gained 15 months without disability and 6 months with disability 49: 
compression of morbidity was thus relative in men, as they gained some time with disability, although in a 
lower proportion than the time without disability. Moreover this compression occurred later than the one 
observed for women. 
 
Although women have a longer DFLE0 than men and gained more disability-free years, the absolute number 
of years spent with disability is higher in women. In 2002, LE0 was 77.8 in men and 83.1 in women, and 
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DFLE0 was 73.7 years in men and 76.8 years in women: thus, on average, men would spend about 4 years in 
a disabled state, versus 6 years for women 50. 
Table 3.  Evolution of LE65 and DFLE65, by gender. (Source: Höpflinger 49, OFS 50 and 
author’s calculations) 
 Men Women 
 LE65 DFLE65 DLE65 DFLE65/LE65 LE65 DFLE65 DLE65 DFLE65/LE65 
1981/82 14.6 11.5 3.1 79% 18.5 12.2 6.3 66% 
Change 1981-
1997 
+ 2.1 + 1.5 + 0.6  + 2.1 + 4.1 - 2.0  
1997/99 16.7 13.0 3.7 78% 20.6 16.3 4.3 79% 
Change 1981-
2002 
+ 3.5 + 3.1 - 0.2  + 2.6 + 3.7 - 1.1  
2002 17.5 14.6 2.9 83% 21.1 15.9 5.2 75% 
4.1 OTHER COUNTRIES 
Caution should be applied when comparing healthy life expectancies among different countries, because of 
the quality of the data often varies, as well as the methods used to assess healthy life expectancy.  
The OECD examined the trends in disability at age 65 years and over resulting from national health surveys 
in 12 countries. There was a clear decline in disability in 5 countries (Denmark, Finland, Italy, The 
Netherlands, the USA), two showed stability (Australia, Canada) and three (Belgium, Japan, Sweden) showed 
an increase. More importantly, the OECD study shows that the prevalence of disability in activities of daily 
living ranges from a low of 7% in The Netherlands to a high of 18% in the United Kingdom, suggesting 
differences in the assessment of disability as a partial explanation for these differences 51. 
The European Community Household Panel provides data and indicators to monitor the trends of DFLE 
between 1995 and 2003. In men, the gain in LE0 was larger than the one in DFLE0. The pattern is similar in 
women, though the changes are smaller. This suggests an expansion of morbidity rather than the 
compression as observed in Switzerland. 
However, when LE65 and DFLE65 are analysed, the gains are similar for both indicators (see Figure 15, p. 
47), like in Switzerland. The gender-specific secular trends of the ratio DFLE65/LE65 are used in Table 4 to 
characterize each EU country, i.e., if the evolution suggests (i) a compression of morbidity (defined as a 
relative change >=5%), (ii) an expansion of morbidity (relative change <= -5%), or (iii) a stability (-5% 
<relative change <5%). 
Table 4 shows a diversity of evolution among these countries. Further, there is no strong correspondence 
across genders, i.e., the same country shows different evolution according to the gender. These differences 
cannot be explained, and might be attributable to methodological and cultural differences, but also to 
changes in institutionalization rates (as the study excludes institutionalised persons).  
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Table 4.  Distribution of countries among categories of secular trends in the ratio 
DFLE65/LE65 (in %), by gender. EU countries, 1995-2001 (Source: Jagger C and 
EHEMU team, European Health Expectancy Monitoring Unit, www.ehemu.org) 
DFLE65/LE65 (in %) trends … Men Women 
… decrease by 5% or more 
(expansion of morbidity, scenario I in Figure 7, p. 20) 
Denmark 
Netherlands 
Portugal 
Sweden 
UK 
Germany 
Greece 
Ireland 
Netherlands 
Portugal 
… is constant 
(stability, scenario II in Figure 7, p. 20) 
France 
Greece 
Ireland 
Spain 
Austria 
Denmark 
Finland 
France 
Spain 
UK 
… increase by 5% or more 
(compression of morbidity, scenario III in Figure 7, p. 20) 
Austria 
Belgium 
Finland 
Germany 
Italy 
Belgium 
Italy 
Sweden 
 
Another study, based on six longitudinal studies on ageing (5 from Europe and one from Israel), reported a 
significant variation of the DFLE65/LE65 ratios across countries 52. Italy had the lowest ratio, amounting to 
75% and 83% in women and men, respectively, and Sweden the highest (83% and 93%). Note that these 
differences essentially result from different patterns in DFLE0 and LE0. For example, Italian men enjoy 
higher life expectancy among the six countries, but wit the lowest DFLE. 
A Dutch study 53 showed that the increasing number of years with disability were in fact related to mild 
disabilities. DLE65 with mild disability increased from 9.9 to 13.9 years in men (from 10.6 to 14.8 years in 
women), while DLE65 with moderate or severe disability showed a slight reduction. This can be interpreted 
as evidence for the theory of dynamic equilibrium, in which the increased prevalence of chronic disabling 
diseases is counterbalanced by a decrease in the severity of the disability induced by these diseases. 
The effect of gender on disability is partly explained by differences in social and health related factors 54. 
However, the association between female gender and mobility problems is independent, probably mediated 
by musculoskeletal conditions and depressive symptoms. An alternative explanation is that women are more 
likely to report disease and disability than men. 
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Japan has limited data on the prevalence of disability, due to the fact studies did not include residents of 
institutions. In 2002, HALE at birth was 72 years for men and 78 years for women d. According to Schoeni 
55, the prevalence of disability declined in Japan between 1993 and 2002. There would have been more than 
1.1 million more disabled elderly in 2002 in an older population totalling 23 millions if disability had been 
constant over that period. Nevertheless, these results should be taken with caution as the decline in disability 
was not accompanied by a decline in functional limitations, suggesting that the results might be partially 
explained by changes in the built-in environment or developments in assistive technology.  
In the US, studies found that the prevalence of disability increased during the 1970s, paralleling the increase 
in life expectancy 56.A decline was then documented during the 1980s, with an acceleration in the 1990s, for 
both mild and moderate/severe disability 57;58: the increase in DFLE for both genders paralleled the increase 
in LE0. However, as a proportion of LE0, DFLE increased only in persons with higher educational status, 
while those with lower education were still experiencing an expansion of morbidity 59. 
The most recent trends in the US have been analysed by Cai & Lubitz for the population aged 65 and over 
60. During the 1992–2003 period, DFLE65 increased from 9.5 to 10.3 years, and DLE65 slightly decreased, 
mainly as a result from a decrease in severe disability and an increase in moderate disability. These trends 
result in HALE of 67.0 years in men and 71.0 years in women d. Finally, a crucial question is to what extent 
the rise in obesity will lead to a reversal in the trends in disability. 
As a conclusion, trends in disability are heterogeneous. Moreover, several studies showed that an increase in 
the reported or diagnosed morbidity is not incompatible with a decrease in disability.   
4.2 SUMMING UP: LESSONS FROM THE PAST 
In Switzerland, life expectancy continues a steady increase that began sometime before the end of the 19th 
century for LE0, and in the middle of the 20th century for LE65. The latter increased at a pace of 1-1.5 
month per year in the 1990s. As in other countries, there is no clear sign that the rise in LE0 might come to 
an end, although the yearly increase is less pronounced since the 1980s. The modal age at death, which can 
be interpreted as the "normal" mean longevity at a given time, fluctuated until the 1920s, and then increased 
steadily, at a yearly rate of 2-3 months. Adult variability of the age at death decreased during the last fifty 
years, compatible with a compression of mortality. 
There was a widening gender gap in LE0 throughout the 1900s, which then narrowed in most countries since 
the late 1980s. Another widening gap in longevity, also in Switzerland, is related to differences in socio-
economic status 61. 
It is unclear what the driving forces of the continuing increase in life expectancy are. 
In Switzerland, the 1950s marked both the end of the epidemiological transition (i.e., with the disappearance 
of infectious diseases as a public health problem) and the beginning of a “post-transition area”, characterized 
by the mortality decline in old and very old people. Causal mechanisms explaining the turning point of the 
1950s are related either to contemporary improvements (i.e., changes directly benefiting the older people like 
antibiotic treatment for pneumonia, pension scheme, etc.), or to past improvements in the corresponding 
birth cohorts. 
                                                     
d  http://www who int/whosis/database [Accessed Feb 21st , 2008] 
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The improvement in the socio-economic environment has been massive in Switzerland after World War II, 
with direct benefits for the older persons at that time. A Swedish study on the period 1861-1999 62 suggests 
that mortality among people aged 90-94 is directly correlated with manufacturing wages (used as an indicator 
of general wealth). It is not obvious to identify massive improvements in the history of birth cohorts born in 
1890 and after (i.e., those aged 60 and over in the fifties): they were confronted with two wars (less dramatic 
in Switzerland than elsewhere, but still a challenge) and a marked economic crisis in the 1930s. 
One can also imagine that the explanation of the continued rise in life expectancy may lie in the self-
propelling nature of some of these health improvements. For example, if younger adults are healthier, they 
get healthier children, who in turn will get even healthier children. This idea of self-propelling improvement 
might also be related to improvement in education. Further, the decline or delay in widowhood related to the 
decline in older persons mortality might also be associated to a longer life expectancy in those escaping to 
widowhood. 
On the other hand, there is no fate dictating that LE0 should continue on the same line. A plateau of LE0, or 
even a decline, has been observed in some European countries, probably related to crises affecting the socio-
economical environment, life styles (in particular, alcohol and tobacco use) or the supply of medical services.  
The favourable trend in LE is associated with a decrease of age-specific disability prevalence during the last 
twenty years in several industrialized countries, including Switzerland. Consequently, DFLE65 increased 
during the last twenty years, as well as the proportion of years spent without disability, suggesting a 
compression of morbidity. Women consistently spend a longer proportion of life with disability, perhaps 
because of the differences in educational, social and health related factors. Globally, the male-female gap is 
lower for DFLE than for total life expectancy 63. 
However, similar to trends in LE0, trends in DFLE are heterogeneous, with some countries showing stability 
or even decrease in the proportion of years spent without disability after age 65. 
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5 FUTURE EVOLUTION OF LONGEVITY AND HEALTHY LIFE 
EXPECTANCY 
Predicting the future of mortality and morbidity means that one has some idea on their past and current 
determinants. Moreover, a model of the interaction between mortality, morbidity and determinants is 
needed. For the sake of clarity, the typology below presents two main approaches of predictions: 
• "demographic" approaches: 
• projections of the past trends of mortality or life expectancy (p. 27) 
• projections based on limit distributions (p.30), 
• "epidemiological" approaches (p.32), i.e., models based on the future evolution of diseases and their 
known risk or protective factors; these approaches include the evolution of healthy life expectancy; 
Other approaches using for example a combination of the above mentioned methods are finally presented. 
5.1 "DEMOGRAPHIC" APPROACHES: PROJECTIONS OF THE PAST TRENDS OF 
MORTALITY OR LIFE EXPECTANCY 
Selected projections of LE0 from demographic approaches are presented in Table 5, p. 35. According to 
Swiss Federal Office for Statistics, the forecasted LE0 in 2050 are 85.0 years for men( ranging from 82.5 to 
87.5 years according to the optimistic and pessimistic scenarios) and 89.5 (87.5 to 91.5 years) for women 50. 
From 2005, the annual increase is thus situated between 4 and 10 weeks for men, and between 4 and 9 weeks 
for women.  
In these approaches, the past trends are either directly extrapolated, or used in mortality models ; several 
scenarios are usually considered (e.g., with various secular changes in mortality ratios, or with various 
reference periods, etc.). 
Projections for the short run typically rely on a linear extrapolation of historical trends in log of mortality 
rates or life expectancy. Most studies in this group use a limit for life span, although others ignore such a 
limit. 
Extrapolation without constraints usually produces implausible results in the long run. For example, linear 
extrapolation of past LE0 trends for Denmark and Japan will lead to huge future differences between these 
two countries because the different past trends 64. The same is true for extrapolation of male and female LE0. 
For example in most countries male and female LE0 are converging. Simple extrapolation of these trends 
leads to crossover with male LE0 exceeding female LE0.  
Thus, choosing an upper limit to life span is a reasonable approach. Among the arguments for a limited 
duration of life 65, the most important is probably the decline of physiological parameters associated with 
ageing in humans, with a loss of 80% of the functional capacity by age 80. A further demographic argument 
is the slowdown of the LE0 increase, as observed in several countries, which can be taken as an argument in 
favour of an upper limit. However, this slowdown is paralleled by an accelerated decline in mortality at older 
ages. Moreover, the fastest decline of mortality has been observed in countries with the lowest levels of old-
age mortality, i.e., the opposite of what is expected if mortality were pushing against an upper limit 66. 
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Although there are biological arguments in favour of an upper age limit, there is debate about the value of 
this limit. The many proposals for the maximum LE0 found in the literature vary between 65 years (as 
proposed by Louis Dublin in 1928) to 85 years 67 (with a maximum life span of 122 years). 
Using a biodemographic approach, Olshansky refers to the schedule of age-specific death rates as an 
“intrinsic mortality signature”, that might change only when the forces of selection acting to maintain the 
genetic composition of a population are disrupted (either through environmental challenges, interventions, 
or diseases). This model estimated the maximum life expectancy being 85 years in 1990 68, with gender-
specific limits of 82 years for men and 88 years for women. To get these estimates, death rates would have to 
decline at every age and for every cause by about 55% from levels existing in 1895. The authors claim the 
magnitude of this change would be equivalent to the elimination of both cancer and heart disease. 
Apart from biological determinants of mortality, man-made determinants should be considered. Studies 
report it is not unlikely that the development of innovative technologies benefiting the health of older 
persons will continue on the same line, contributing to the lowering of death rates 69;70. 
Another important issue is to set the observation period used for the linear model. Janssen and Kunst 71 
explored systematically the impact of choosing two reference periods (25- or a 50-year) on the projected 
mortality of people aged 80 and more up to 2050 in seven European countries (Switzerland not included). 
The objective was not to produce a forecast, nor to recommend a specific technique, but to show the 
different ways in which mortality forecasts could integrate knowledge about past mortality trends (reflecting 
the effect of duration of the historical period, sex, smoking and country). As recommended by Wilmoth21, 
the projections used indirect extrapolations of age-specific mortality rates instead of life expectancies because 
the latter has proved to be less insightful owing to lack of information on underlying changes in age-patterns 
of mortality. 
Choosing a reference period of 25 years (1975-1999) instead of 50 (1950-1999) resulted in gains in LE80, 
higher in men, but lower in women 71; this obviously reflects the gender-specific changes in the secular 
trends. On average, for the seven countries together, the gain in life expectancy at birth at age 80 in men in 
the period 1999-2050 was 1.72 years and 2.13 years using the periods 1950-1999 and 1975-1999 as projection 
base, respectively. In women, corresponding figures were 3.78 and 3.39 years 71. 
Using non-smoking related mortality trends only 71, gains in life expectancy were usually higher than those 
calculated using all-cause mortality. The projections based on non-smoking mortality should be considered 
with caution, as levels of smoking-related mortality were only estimated: detailed data were lacking. In men, 
the impact of the period used to project life expectancy also illustrated trends in smoking mortality, as using 
the period beginning in 1950 led to a higher projected gain 71. 
Projections by country show substantial differences in the magnitude of the gain in LE80, explained by the 
variations in the pace of decline in old-age mortality over time. For example, for Norway, the stagnation of 
old-age mortality decline in the 1950s-1060s results in a lower gain in LE80 when using the period 1950-1999 
instead of 1975-1999 as projection base.  
The Lee-Carter method and its variants are the most frequently used methods to forecast mortality 72;73. It is 
based on the linear decomposition of the logarithm of observed force of mortality at age x during year t (µx(t) 
into (i) a dominant component changing with calendar time, and (ii) an age component that remained fixed 
over calendar time. 
As for linear projections of log of mortality rates, the Lee-Carter method may produce implausible age 
patterns in the long run if any rate trends differ, because these differences will be magnified in the 
projections. 
By its very nature, the Lee-Carter method is extrapolative and projecting mortality in this way is likely to 
result in a continuous increase in life expectancy. Moreover, the forecasts (even when based on similar 
extrapolative procedures) are likely to imply increasing divergence in life expectancy in the long run. This 
contradicts the observation made by Wilson who documented a global convergence in mortality 74. Li and 
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Lee considered how a particular extrapolative method can be modified to forecast mortality for countries by 
taking into account their membership in a group, rather than individually 64. 
This method was used to model observed and forecasted sex-specific life expectancies and longevity in the 
United States from 1900 to 2065 75. The method is currently used by the US Bureau of the Census. 
Besides the application of the method to several countries by Lee 73, the Lee-Carter method have been used 
in the G7 countries projections, and in long-range projections for the UN Population Division 76;64;77. 
In the model proposed by the U.N. Population Division, based on the Lee-Carter method as modified by Li, 
the increments of LE0 over time decrease as higher levels of LE0 were reached 78. This allowed to limit LE0 at 
92.5 years in the medium-range projections. 
For the long-term projections, the choice was made not to cap future LE0 to 100 years, providing allowance 
was made for the necessarily modified shape of mortality schedule. Because the Lee-Carter method might 
produce divergence of LE0  (instead of convergence) in the long-range projections, there was a proposal by 
Lee to modify the method to ensure non-divergence. In general, in the normal mortality scenario, mortality 
is projected on the basis of the models of change of LE0, using the period 1980-2000 as projection base, and 
choosing a medium pace of mortality decline. The long-range projections used a cohort-component method 
for the 100 years of projection then a simpler method for the rest of the projection period. 
The Lee-Carter method has been compared to four variants (Lee-Miller, Booth, Hyndman-Ullah, De Jong-
Tickle). The variants performed better in forecasting death rates, but there were no significant differences in 
accuracy for the short-term forecasts for life expectancy 79. 
Retrospective projections suggest that the Lee-Carter method tended to underestimate the gains in the US, 
but did well in France, Sweden, Japan, and Canada 80. On the other hand, one of the Lee-Carter assumption 
(the decline of mortality at each age remains constant over time) contradicts current observations, i.e., the 
decline of mortality slowed down at younger ages and rose at older ages. 
To overcome this limitation of the Lee-Carter method, a "shifting" logistic model has been proposed by 
Bongaarts 81, in order to capture the age-specific pattern of secular change in age-specific mortality. In this 
model, the shape of the pattern of mortality rates by age is held invariant while the pattern itself shifts to 
higher ages over time as life expectancy rises. The projections made according to the Bongaarts' model 
compared well with the Lee-Carter one, being more robust when long range projections are concerned. 
Pedroza 82 developed a Bayesian approach which incorporates several sources of variation in the model 
when forming forecasts, and allow to handle missing data both in the time series and across age groups. It 
also takes into account the uncertainty associated with it.  
Babel et al. 83 recently developed a mortality model incorporating the "volatility" of mortality, containing two 
separate dimensions: (i) a common time effect over all ages and (ii) a common age effect of mortality 
evolvement. The time effect denotes the common level of mortality growth/decline, while the age effect is a 
stochastically independent age-specific term. Using a common time period from 1959 to 2002, life 
expectancies for 12 regions (including the Alps region, represented by Austria and Switzerland) are estimated 
in 2050. Beside traditional period life expectancies, more realistic but less commonly used cohort life 
expectancies are also calculated. 
Using data from 1950 to 1999 in 7 European countries (excluding Switzerland), Janssen and Kunst 71 predict 
an increase of LE80 averaging 2.3 years among men and 4.0 years in women by 2050. Assuming unchanged 
mortality rates at younger ages, a 2.3 years increase in LE80 would lead to an increase in  LE0 of 1.0 year in 
men and 2.5 years in women. As a comparison, adding these estimates of increase to LE0 observed in 2000 
in Switzerland results in projected LE0 for 2050 of 78.2 and 85.5 years for men and women respectively, 
somewhat lower than the pessimistic scenario by SFOS. 
 30 
 
Bongaarts examined trends in life expectancy when decomposed into juvenile, background, senescent and 
smoking-related mortality 26. After removing the effects of juvenile, background and smoking mortality, the 
average rate of increase in senescent life expectancy over the past 50 years was 0.15 years per year, and was 
almost linear. 
For projecting LE0, Bongaarts assumes that this trend is likely to continue for a few more decades, as there is 
no reason to believe that technological and medical advances will be less effective in reducing senescent 
mortality in the future than in the past. On the contrary, his model makes allowance for the future 
disappearance of the effect of declining juvenile and background mortality. Projections of life expectancy to 
2050 for the two sexes based on this decomposition model (projecting separately trends in juvenile, 
background, senescent and smoking mortality) show that LE0 is likely to increase by an average of about 7.5 
years up to 2050 depending from the country (see Table 5, p. 35). Although less optimistic than those of 
Oeppen and Vaupel, because they assume little impact of further improvement in juvenile mortality, 
Bongaarts’ projections are more optimistic than those of the United Nations. 
Several authors provide confidence intervals around the estimates, generally increasing with the duration of 
the period of projection. For example, Lee and Carter forecasted a LE0 increase of 10.5 years between 1990 
and 2065, reaching 86.0 years with a confidence interval between 80.9 and 90.2 years. For 2050 and for 
Switzerland, Babel forecasted a 90% confidence interval for LE0 of 4.9 years (for the period-related data) and 
6.6 years (for the cohort-related data) in men; corresponding values for women are 5.6 and 9.2 years 83. 
Providing sound confidence intervals was one of the aim of Pedroza in his Bayesian approach of the Lee-
Carter model 82. 
Those avoiding the use of a life expectancy argue that this assumption repeatedly proved to be too 
conservative. Using the last 160 years showing a strikingly linear increase of LE0 in women, the model used 
by Oeppen and Vaupel projects life expectancies throughout the 21st century by continuing this trend 84.  
5.2 "DEMOGRAPHIC" APPROACHES: PROJECTIONS BASED ON LIMIT 
DISTRIBUTION 
As noted above (p.27), demographic approaches include some assumptions on the extreme levels of 
mortality which will be reasonably reached. These approaches include combination of the lowest mortality 
rates observed by sex-age groups, or gaps between countries (i.e., considering the time needed by a specific 
country to catch up the most advanced countries), or estimate the lowest achievable cause-specific death 
rates. Some results of these approaches are displayed in Table 6, p. 36. 
Achievable life expectancy can be estimated by combining the lowest mortality rates observed worldwide. 
Uemura collected the lowest age-specific mortality rates observed worldwide from 1950 to 1980, and 
calculated a potentially achievable LE0 of 76.2 years in men and 82.1 years in women 85 (see Table 6, p. 36). 
As a comparison, observed LE0 in Switzerland in 1980 was 72.4 for men and 79.1 for women 50, and 
surpassed in 1999 the values calculated by Uemura. 
More recently, Vallin and Meslé used a similar approach by combining the lowest age- and cause-specific 
mortality rates worldwide from 1950 to 2000. In 2000, the resulting LE0 would reach 84.4 years in men and 
88.9 years in women. A comparison between the highest observed LE0 and the potential LE0 resulting from 
the model showed that observed LE0 reached potential LE0 about 25-30 calendar years later (see Table 6, p. 
36) 86. This is similar to Uemura’s findings. This suggests that the potential LE0 of 84.4 years (men) and 88.9 
years (women) might be reached in the next two or three decades in countries with the highest current LE0. 
These values fall into the range of values estimated for Switzerland in year 2050: 82.5-87.5 for men and 87.5-
91,5 for women 50. 
 31 
 
Eradication of one or more causes of deaths and the resulting change in mortality rates have been used to 
predict achievable gains in life expectancy. One of the problems here is the interdependency between causes 
of deaths 87. 
In the 1970’s, Tsai examined the potential gains in LE0 when the three leading causes of death are totally or 
partially eliminated. The impressive gains theoretically achieved by total elimination do not hold up under the 
more realistic assumption of partial elimination or reduction. The number of years gained by a newborn 
child, with a 30% reduction in cardiovascular disease, would be 1.98 years, for cancer, 0.71 years, and for 
motor vehicle accidents, 0.21, years. Simulating the same reduction for the working ages (15 to 70 years) 
results in a gain of 0.43, 0.26, and 0.14 years, respectively for the three leading causes of death. The author 
concluded that even with a scientific breakthrough in combating these diseases, future gains in life 
expectancies for the working ages will not be spectacular 88. 
Nusselder estimated the gain in life expectancy resulting from the elimination in selected chronic diseases 89. 
For example, eliminating heart diseases added 3.1 years for men and 2.7 years for women to LE65, while 
eliminating cancers added 2.7 years and 1.9 years, eliminating diabetes added 0.1 to 0.3 years, for men and 
women, respectively (see Table 6, p. 36). The elimination of other chronic diseases, such as chronic 
obstructive pulmonary diseases or Parkinson disease, had a negligible effect on life expectancy. Authors did 
not try to estimate the cumulated gain resulting from the cumulative elimination of several groups of 
diseases. 
Oeppen and Vaupel recommended using the observed gaps between countries and regions: the life 
expectancy in the countries with the highest life expectancy can set as the achievable limit for all 84. This 
approach is close to the one computing life expectancy based on the lowest mortality rates. However, this 
approach is less significant in Switzerland which has the second highest life expectancy worldwide. 
The models based on the "rectangularization" of the survival curve belong to these "analytical" approaches. 
The theory states that at a given period, there is strong compression of mortality around a given age (and a 
stiffer resistance to further increase is expected), without stating what will be the value of this limit. 
Based on the inverse relationship between the modal age at death (M, see p. 7) and the standard deviation of 
the age at death above the mode (SD(M+), see also p. 7), Kannisto developed his hypothesis of an “invisible 
wall” to the extension of human longevity 15: as the modal age at death increases, the right-hand slope of the 
distribution of age at death becomes more and more vertical. 
Up to now, there are few observations backing up this hypothesis. One study reported clear signs of 
verticalization in Switzerland between 1969 and 1994, using the trend in distribution of age at death after 50 
year 20. Recent studies noted that rectangularization might slowly come to an end, with a shift of the 
mortality towards older ages 90. 
There are few published data about the future evolution of SD(M+). A model of the curvilinear relationship 
between M and SD(M+) can be used to estimate the values of SD(M+) if M goes on increasing up to 95 
years. Using data from France, Italy and Japan, SD(M+) was estimated to decrease up to the values of 5.5 to 
6.5 years when M reaches the value of 95 years, while for Sweden, SD(M+) might take the value of about 4.5 
years. This curvilinear relationship however suggests that SD(M+) will eventually reach some kind of floor 
values 91. 
It is indeed unlikely that the survival curve will become totally rectangular, due to the heterogeneity of the 
human population, so that the question remains up to what degree of rectangularization the survival curve 
will evolve. 
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5.3 "EPIDEMIOLOGICAL" APPROACHES: PROJECTIONS BASED ON HEALTH-
RELATED INFORMATION 
These models are using information related to the future evolution of lethal, degenerative diseases, which 
represents the major burden in ageing populations: in developed countries, heart disease, cancer and 
cerebrovascular disease are responsible of 60% of all deaths of people aged sixty-five or older 23. 
Obviously, the credibility of the projections depends on the current knowledge about the evolution of 
known determinants of these diseases, i.e., the risk or protective factors related to the physical and social 
environments, to life styles, to health care and even to the genetics. The future of climate change, inequalities 
in health, diet, technological innovation or migration are classical examples. Factors considered in this report 
will be cardiovascular risk factors and diseases, smoking, cancers, and genetics. 
These approaches are based on the expected future trends in prevalence of diseases and their determinants. 
Olshansky claimed that the reason why official forecasts consistently underestimated mortality was their 
reliance on static extrapolation of past trends, neglecting medical, behavioural or social factors that influence 
mortality 92. Therefore, he proposed a "multiple cause-delay model" to capture the impact of more 
favourable risk factors on mortality.  
Because of its frequency, cardiovascular disease (CVD) might be the single most important determinant of 
the future of longevity. An analysis of mortality of people aged 75-84 years in Europe between 1970 and 
1996 showed that the decline in total mortality was almost entirely due to the decline in CVD mortality, 
especially stroke 93. Mean blood pressure has fallen in Switzerland as in most developed countries 94;95, and 
this probably is the most important determinant of the decline in stroke mortality.  
CVD mortality declined in most developed countries 96. In Switzerland, the decline of incidence between 
1985 and 1993 was 3.6% for men97. This secular decline is more marked as age increases, and its impact is 
therefore more marked in an ageing population 97-99. Further, available evidence show that there is still a 
room for improvement 100 for diet 101;102 (including the reduction of salt consumption 103;104), sedentarity, 
tobacco consumption, etc. There is also room to improve the care of hypertensive and dyslipidemic patients 
97;105. However, increases in total CVD mortality were recently observed in some central European countries 
and Greece. In the United Kingdom, CVD mortality among young men recently increased for the first time 
since two decades, perhaps as a consequence of unfavourable trends in risk factors, especially obesity and 
diabetes 106.  
CVD mortality also matters to explain the gender difference of overall mortality. Currently, gender 
differences in CVD mortality rise steeply with age in parallel for both genders, but the female rates are those 
observed 5-10 yr earlier in men 107. In the US, the levels of elevated blood pressure (with or without 
medication) have declined for older men but have increased for older women 23. 
Trends in cancer incidence are heterogeneous. Between the 1960s and 2002, the contribution of a reduced 
cancer mortality to the increasing LE0 was less than 1 year, as compared to a contribution of almost 3 years 
from cardiovascular diseases 108. However, because of the decline in CVD mortality, the cancer mortality 
increased its contribution to the overall mortality decline after 1990. 
The evolution of gender differences in mortality is consistent with smoking patterns. Recent changes will 
probably reduce sex differences in mortality in the coming decades 109. An analysis of the trends in male and 
female life expectancy and of the proportion of deaths attributable to smoking allows determining the effect 
of smoking on LE0 26. In year 2000, data from 16 countries suggested that smoking reduced LE0 by 1.0 year 
in women and 2.4 years in men; corresponding figures for Switzerland were 0.5 and 1.9 years. 
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Janssen and Kunst 71 explored systematically the impact of choosing non-smoking related mortality instead 
of all-cause mortality, this approach yielded to higher gains of life expectancy in women. Bongaarts also 
estimated the impact of smoking on trends in LE0 during the last 50 years. Even after eliminating the effect 
of smoking, LE0 remains lower in men than in women. 
Because of its consequences on CVD, diabetes and cancer, obesity might play a crucial role in the evolution 
of longevity in the next decades, as its prevalence increases in several industrialized countries. According to 
Olshansky 110, LE0 was reduced by 4-9 months in the US in 2000 because of the current frequency of 
obesity. Based on its future trends, obesity could reduce LE0 by two to five years in the coming decades (see 
Table 6, p. 36). 
An effective control of hypertension could add 75 million DALYs, and eliminating diabetes would add 90 
million life-year equivalents 111. 
Body mass index (BMI) also increased among older people. In the US, after remaining roughly stable in the 
1970s, the proportion of non-institutionalized older women and men who are obese (BMI > 30kg/m2) 
increased among older men from 19 percent in 1988–1994 to 26 percent in 2001–2004, and among older 
women from 23 percent in 1988–1994 to 31 percent in 2001–2004. As a consequence, the prevalence of 
diabetes has increased among older people in several countries. In the US, this increase was from 18% in 
1988–1994 to 25% in 2001–2004 23. 
In Switzerland, obesity currently affects about one in ten adults, but overweight is found in almost one in 
two persons. However, the effect of overweight on longevity seems negligible 112. 
However, the relationship between obesity and CVD is more complex than initially thought. In the US, 
obesity did increase between the 1970s and the early 2000s, but the overall cardiovascular risk profile of the 
population has improved, mainly because of the reduction in smoking and better control of blood pressure 
113. Another study showed that the association between BMI and blood pressure has decreased over time 114. 
Diet has an substantial effect on survival 115. A healthy Mediterranean-type diet has been shown to reduce 
mortality risk by 30% in older women 116.  
Genetic influences on human life span and longevity are under study. Within a given birth cohort, there are 
considerable variations in life span. Twin studies suggested that about one quarter of the overall variation in 
lifespan might be accounted for by genetic differences 117;118. 
The rapid increase in LE0 throughout the past century is unlikely to be due to genetic factors, although some 
authors believe that there is a possible role for a selection mechanism favouring long survival 119. 
The impact of health services on longevity are debated and thus, the impact of potential developments in 
health care. Some experts claim that major discoveries are likely in the next few decades and that they will 
impact on life expectancy 120;121, while others are sceptical 122. In any case, there is still room for improvement 
only by a better coverage of people with existing effective intervention, e.g., by increasing the coverage by 
vaccination 23. 
With joint replacements (knee and hip), cardiac revascularization procedures (angioplasty and bypass surgery) 
has become a substantial part in improving functioning and quality of life in recent years. The rate for bypass 
surgery increased during the 1980s and 1990s. Coronary angioplasty was introduced in the late 1970s: 
between 1995 and 2004, its rate was doubling, with the largest increase occurring among people aged 85 and 
more 23. 
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Diehr et al. estimated the impact of five interventions on mortality on people aged 65 and more 123. 
Longevity could be increased by 3 months as the result of a one-shot intervention that would make healthy 
all sick people at baseline. An improvement of similar magnitude could be obtained from an intervention 
decreasing the probability of getting sick each year by 12%, or from an intervention increasing the 
probability of a sick person recovering by 16%, from an intervention decreasing the probability that a sick 
person dies by 15%, or from an intervention decreasing the probability that a healthy person dies by 14% 123. 
5.4 CONCLUSION  
 Apart from demographic and epidemiological approaches, other experts use approaches that combine 
demographic approaches with analytical, epidemiological and biological approaches. However, these 
approaches have been more frequently used as theoretical bases, and there is less literature containing 
projections based on these theories. 
The process of ageing itself can be a central aspect of the theory underlying the future evolution of longevity 
as a large part of the ageing might be related to biological phenomenon 124. 
The search for a single cause of aging has recently been replaced by the view of aging as an extremely 
complex, multifactorial process 125. The different theories of aging are now considered as complementary. 
A straightforward and simple approach 67 attributes age-related changes to genetic defects, perinatal and 
post-natal development, environment, disease, plus an inborn process, aging itself. Accumulation of 
deleterious changes produced by aging throughout the cells and tissues progressively impairs function and 
can eventually cause death. The mortality at a given age is a measure of the cumulated change at that age (the 
physiologic age), and the rate of mortality change is the rate of aging. 
Risk of death is now largely determined by the inherent aging process after age 28. Only 1.1% of female 
cohorts in Sweden die before this age; the remainder die off at an exponentially increasing rate with 
advancing age. 
According to this theory, risk of death in developed countries are now reaching limiting values: LE0 is 
approaching plateau values that are 6-9 years less than the potential maximum of about 85 years 67. 
On the contrary, according to a theoretical model combining information related to both trends in cell 
growth and in survival 126, life span could increase beyond 120 years. In fact depending from what types of 
cells is considered, this maximum value varies between 98 and 126 years. Relevant mechanisms may be partly 
related to endocrine control 127. 
Among other research on ageing, it has been shown that long-term caloric restriction may extend the life of 
the laboratory rat by about 25%. Although most humans would not adhere to such a diet as the one imposed 
on laboratory animals, research in humans has shown that a 20-25% reduced caloric intake is able to 
improve risk factors for cardiovascular diseases, and biomarkers for longevity (deep body temperature and 
plasma insulin) and thus, should increase life expectancy. 
Using information from the survival studies of overweight and obese people, it is estimated that long-term 
reduced caloric intake to prevent excessive weight gain could add 3-13 years to life expectancy. However, the 
effects of caloric restriction on human life extension are probably much smaller than those achieved by 
medical and public health interventions: these have extended life by about 30 years in developed countries in 
the 20th century, by greatly reducing deaths from infections, accidents, and cardiovascular disease 128. 
Although several studies on animal models have shown that aging rates and life expectancy can be modified 
by "anti-aging" remedies, there is currently no evidence that these substances can slow aging or increase 
longevity 129. 
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Based on projections of future economic and social development, and using historical relationships of 
economic and social development with cause-specific mortality rates, the WHO published projections of 
LE0 to 2030 in several regions of the world 130. According to this analysis, LE0 is thought to increase in all 
regions of the World, provided future mortality in low income country will have a relationship to economic 
and social development similar to those that have occurred in higher-income countries. The increase in LE0 
in high income countries should reach 4-5 years in men and women, with a range of about 1.5 years between 
the pessimistic and the optimistic scenarios. 
A complete scenario of future trends in longevity should also include projections of modal age at death, as 
well as insights about the future evolution of the survival curve in terms of rectangularization. Unfortunately, 
we are not aware of published work using these indicators. 
Table 5.  Values of projected LE0 for 2050 in selected countries. 
 Swiss federal of Statistics, 
2006 50  
Babel & al. 2007 83 Tuljapur-
karS,  
2000 131 
Li & Lee 
2005 64 
U.N. 
Population 
Division, 
2007 132 
Bongaarts J, 
200626 
 
Projection 
method 
 Period/cohort approaches 
(see p. 29)  
Stochastic 
forecast 
Converg-
ence of 
mortality 
Lee-Carter  decompositio
n of 
mortality 
 M W M W M+W M+W M+W M W 
Switzerland 
85.0 (82.5-
87.5) 
89.5 (87.5-
91.5) 
  - 86.5 82.9 84.5 90.2 
Switzerland 
and Austria 
  82.1/89.1 87.3/94.0      
Japan - - 87.0/97.0 94.5/103.6 90.9 88.1 88.1 85.2 92.1 
France - - 82.0/89.5 89.4/96.8 87.0 85.8 84.0 82.8 90.3 
Germany - - 81.4/88.1 87.5/95.0 83.1 84.8 83.5 - - 
United States - - 80.4/87.3 84.9/91.4 82.9 84.9 81.6 81.6 87.0 
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Table 6.  Projected LE0 according to selected approaches 
 Nusselder et al.  
1996 89 (see p.31) 
Uemura 1989 85 
(see p.30) 
Vallin & Meslé 
(unpublished) 86 (see 
p. 30) 
Olshansky 
2005 122 
(see p. 33)  
Mathers et al. 
2006 130 
(see p. 34)    
Projection method Elimination of 
selected disease 
 
Lowest age-specific 
mortality rates 
worldwide 
Lowest age- and 
cause-specific 
mortality rates 
worldwide 
Impact of 
obesity 
Cause-specific 
mortality rates 
 Potential change in life expectancy at the time of analysis 2030 
 M /W M /W M /W M+W M /W 
Increase in LE0 From CVD: 
+ 3.1/+ 2.7 yrs 
From cancer: 
+ 2.7/+ 1.9 yrs 
+2.5/+3.0 yrs +5.4/+5.0 yrs USA: 
- 3-4 months 
High-income 
countries: 
85.0/79.7 
5.5 DETERMINANTS OF HEALTHY LIFE EXPECTANCY 
Healthy life expectancy (HLE) depends on the burden of chronic diseases that may result in disability. Past 
trends in the evolution of HLE showed different evolutions between countries, within countries and 
between genders. Expectedly, there is currently a lack of consensus about future trends in HLE. 
Projections of HLE rely on projected total life expectancy, combined with projections of the prevalence of 
disability. Trends of the latter have been favourable over the past twenty years. Based on information on 
younger cohorts, the prevalence of disability is projected to further fall until about 2015, then to stabilize and 
even rise slightly 134. 
Moreover, the rising rates of obesity and diabetes might well reverse disability trends 23. The consequence of 
obesity on disability-free life expectancy is a loss of about 2.8 years of years of healthy life, even if LE0 is not 
substantially reduced 135. A trend analysis in obesity between 1985 and 2002 in middle-aged Americans, with 
an extrapolation to 2020, found that disability rates will increase by 1 percent more than if there were no 
further weight gain 136. 
Some recommend against extrapolating recent trends in disability forward into the future, because of the 
complex determinants of disability. In particular, the development of new assistive technologies might have 
contributed to the fall in reported disability 137. 
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Using a similar approach as Nusselder for LE0, Ezzati computed health-adjusted life expectancy in the 
absence of 20 major risk factors for diseases and injuries. The burden of disease attributable to the joint 
effects of 20 selected leading risk factors were assessed and population attributable fractions for these risk 
factors were estimated using information about risk factor prevalence and about the associated risk of 
disease. The population attributable fraction represents the proportional reduction in disease or mortality 
that would occur if exposure to a risk factor were reduced to an alternative level. In Western Europe, 
removing these risk factors would increase health-adjusted life expectancy by about 5 years as compared to 
the current situation in 2000 138. 
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6 SUMMING UP AND RECOMMENDATIONS 
In summary, all methods of projection predict that LE0 will increase up to 2050 in men as in women in 
industrialized countries such as Switzerland, within a range of values of five to nine years 83. 
Most projections of life expectancy use historical trends in mortality rates or life expectancy as an input, 
viewed as the most reliable method of predicting the future trends 21. The main argument in favour of this 
approach is the remarkable stability of the changes over the past 200 years. It has been noted that the 
increase in life expectancy has occurred parallel to improvements in social context and medical care, but also 
included events with substantial demographic impact, such as the 1918 Spanish Flu, or wars. Further, it is 
claimed that any alternative methods of projection require a better understanding of underlying mechanisms 5. 
On the other hand, previous projections based on past trends very often underestimated the increase in life 
expectancy, partly because of the belief that the main causes of longevity improvement in the 20th century 
were on-off gains that could not be repeated 139. Moreover, these extrapolative approaches neglect available 
information on past and future determinants of mortality and morbidity. In Switzerland for example, it 
seems that the 1950's have been a pivotal period with the start of the decline of the old age mortality. 
It should be noted that projected values obtained through analytical and/or epidemiological hypotheses are 
not very different from those provided by extrapolative methods. But they are in a way more credible 
because based on some sort of logical information structure. 
Despite available biological evidence, theories regarding an upper limit to life expectancy do not have much 
support.  
Changing rates of specific chronic diseases (diabetes for example) and their determinants (obesity for 
example) will, at least in the short term, have a bigger impact on the years of life spent with disability rather 
than on life expectancy, although the observed increase in diabetes among younger adults might ultimately 
lead to higher death rates. 
Recent trends in the proportion of healthy life expectancy are divergent across European countries. Whether 
these results indicate real variation or differences in measurement of disability is still undetermined. Robine 
and Michel claim that the compression and expansion of morbidity coexist, each of them being more 
prominent at a time 140. 
According to the general conclusions, two recommendations are proposed below, the first about making 
predictions, the second about the information system. 
6.1 MAKING PREDICTIONS 
There is currently no definite argument in favour of one unique, specific method: we thus recommend to 
publish regularly (e.g., on a 5 years basis) projections based on several methods rather than on a single one. 
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In practical terms, this means that SFOS should continue to provide projections based on the usual 
demographic methods, plus to provide at least three other different projections, namely (i) a method using a 
set of observed lowest mortality rates at a given time (see p. 30), (ii) a method using the epidemiological 
projections of the main determinants (e.g., smoking, diet, etc.) of CVD mortality (see p. 32), and (iii) a 
method estimating the effect of the projected evolution of education 61 and socio-economic status on the 
future mortality rates. 
Current demographic methods used by the SFOS should be complemented by several new developments. 
One is to refine the use of historical trends and to use a historical period at least as long as the projection 
period 71. A further development is to take into account the mortality experience of other populations, as 
suggested by Li and Lee (see p. 28). Further, the cohort effects should be considered, i.e., the mortality at 
young age should be analysed to determine whether recent trends in old-age mortality are likely to persist 
into the future. 
As for the limit to life span, there is no available evidence of such a limit, and there are few signs that we are 
approaching this limit: in fact, ongoing studies in Switzerland suggest that we have a rectangularization of the 
survival curve, plus an increasing mean duration of life. 
The three methods suggested earlier (see above) needs a closer collaboration between demographers and 
epidemiologists. The best way to achieve this collaboration is to set up a formal group working regularly on 
the theoretical and practical issues related to the use of the three methods. 
Within the framework of the development of health-related indicators for the use of the three methods, 
more will be available to provide regularly estimates of healthy life expectancy. Its importance will grow as 
the burden of our ageing societies on the health and social services will be highly influenced by the number 
of years older persons spend in a disabled state. In other words, there is a need to monitor the health status 
of the oldest old, in order to estimate future age-specific needs for health and social services. Projections 
related to mortality and healthy life expectancy will be provided at the same time. 
6.2 DEVELOP APPROPRIATE INFORMATION SYSTEMS  
A closer monitoring of longevity is needed. In practical terms, this means that mortality rates of the oldest-
old (i.e., after 90) should be followed up not only with cross-sectional estimates, but also with cohort. The 
implementation of the Swiss National Cohort, a joint initiative of the Swiss Federal Office of Statistics and 
the Swiss Institutes for social and preventive medicine 61 should help in this perspective 141. 
In order to develop methods using health related information, epidemiology in the oldest population should 
be improved142. There are at least two practical proposals. The first is to develop the health surveys 
addressed to elderly people. The Swiss health survey should systematically include a sample of 
institutionalized population, for this is a substantial part in this age range. 
A second aspect is to rethink the system of cause of death. As it is, it is useless for the majority of deaths 
occurring after 80 years because the information content is low. Several initiatives, experiments and pilot 
studies are needed to prepare a change in the registration system. This could be a topic for a national, or 
even international, R&D programme. 
Implement innovative research Finally, a program of research aiming at disentangling the social and health 
care effects on mortality is needed. This is particularly important as the social expenses (e.g. housing) are in 
concurrence with the medical expenses. 
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As far as migration is concerned, Switzerland has traditionally a strong immigration policy, as reflected by the 
20% of foreign persons, but the mortality pattern of this population is still unclear, as well as its impact on 
longevity in Switzerland. 
Finally, in the context of a continuously increasing longevity engendering the emergence of a frail 
population, at risk for becoming disabled, the study of frailty also deserves much interest. 
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7 APPENDICES 
Figure 9.  Evolution of LE0 since 1825. Women, selected European countries (Source: 
European Health Expectancy Monitoring Unit, www.ehemu.org 
 
 
Figure 10.  Evolution of LE0 since 1825. Men, selected European countries (Source: European 
Health Expectancy Monitoring Unit, www.ehemu.org) 
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Figure 11.  Three pattern of evolution of LE0 since 1945 (i) "high convergence group", i.e., 
LE0 at the highest level in Europe, (ii) "low convergence group", i.e., LE0 at 
about 2 years lower than the highest level in Europe, (iii) "divergent group", LE0  
diverging from overall trend. Women, various European countries (Source: 
European Health Expectancy Monitoring Unit, www.ehemu.org) 
 
 
 45 
 
Figure 12.  Three pattern of evolution of LE0 since 1945 (i) "high convergence group", i.e., 
LE0 at the highest level in Europe, (ii) "low convergence group", i.e., LE0 at 
about 2 years lower than the highest level in Europe, (iii) "divergent group", LE0  
diverging from overall trend. Men, various European countries (Source: European 
Health Expectancy Monitoring Unit, www.ehemu.org) 
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Figure 13.  Evolution of LE65 since 1825. Women, selected European countries (Source: 
European Health Expectancy Monitoring Unit, www.ehemu.org) 
 
 
Figure 14.  Evolution of LE65 since 1825. Men, selected European countries (Source: 
European Health Expectancy Monitoring Unit, www.ehemu.org) 
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Figure 15.  Trend in life expectancy and DFLE65 in several European countries, 1995-2003, by 
gender. (Source: European Health Expectancy Monitoring Unit, www.ehemu.org) 
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